Pelvic Floor Repair Systems for Prolapse Repair
Launched by ASTORA WOMEN'S HEALTH · Mar 18, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • -Have been diagnosed with one or more clinically significant anterior, apical or posterior genital prolapse disorder(s) (symptomatic POP-Q stage II or higher) requiring surgical repair
- Exclusion Criteria:
- • The Investigator determines the subject is not a candidate for surgical repair of her genital prolapse.
- • Subject has had a prior prolapse implant/procedure (i.e., IVS tunneler, Perigee, Apogee, graft augmented repair, etc) Note: previous traditional repairs are allowed.
- • Subject has active or latent systemic infection or signs of tissue necrosis.
- • Subject has restricted leg motion (inability to abduct or adduct leg positioning in the lithotomy position) with or without a hip replacement/prosthesis.
- • Subject is currently pregnant or intends to become pregnant during the study period. Note: the risks and benefits of performing the procedure if the subject is planning future pregnancies should be carefully considered.
- • Subject has had radiation therapy to the pelvic area.
- • Subject has pelvic cancer, has had pelvic cancer within the past 12 months or has been on cytostatic medication within the past 12 months.
- • Subject has a known hypersensitivity to the graft material(s).
- • Subject has uncontrolled diabetes.
- • Subject is on any medication which could result in compromised immune response, such as immune modulators.
- • Subject was involved in any other research trial \< 30 days of enrollment into this study.
- • Subject has undergone previous pelvic surgery \< 6 months prior to enrollment in this study.
- • Subject is unwilling or unable to give valid informed consent.
- • Subject is unwilling or unable to comply with the requirements of the protocol, complete all Quality of Life questionnaires and return for all follow-up visits.
- • Subject is contraindicated based on intended use and warnings in the AMS PFR System devices for prolapse repair Instructions for Use (IFU).
About Astora Women's Health
Astora Women's Health is a pioneering medical device company dedicated to improving women's health outcomes through innovative solutions. Focused on developing and commercializing advanced technologies for gynecological conditions, Astora aims to empower healthcare providers with effective tools that enhance patient care. With a commitment to rigorous clinical research and collaboration with medical professionals, Astora strives to address unmet needs in women's health, ensuring safety, efficacy, and improved quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norfolk, Virginia, United States
Wellington, Florida, United States
Plymouth, Minnesota, United States
Alpharetta, Georgia, United States
Idaho Falls, Idaho, United States
Paw Paw, Michigan, United States
Downey, California, United States
Portland, Maine, United States
Portland, Maine, United States
Whitinsville, Massachusetts, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Gastonia, North Carolina, United States
Englewood, Ohio, United States
Columbia, South Carolina, United States
Memphis, Tennessee, United States
El Paso, Texas, United States
Leuven, , Belgium
Montpellier, , France
Paris, , France
Paris, , France
Rouen, , France
Strasbourg, , France
Alzey, , Germany
Munich, , Germany
Amsterdam, , Netherlands
Barcelona, , Spain
Leicester, , United Kingdom
Patients applied
Trial Officials
James C. Lukban, DO
Principal Investigator
Eastern Virginia Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials